Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 23

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 23
---
0625 per Warrant Share under the Warrant. At the end of the Repurchase Period (the “Expiration Date”) and provided that there are outstanding Warrant Shares exercisable under the Warrant, the Investor will automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to the Investor one (1) ordinary share for every ten (10) outstanding Warrant Shares exercised under the Warrant. At any time following a breach of any term or condition of the Warrant or of any covenant of the Securities Purchase Agreement between the Company and the Investor, dated November 26, 2025 (the “Purchase Agreement”), the Investor will have the right to make a “cashless” exercise of the Warrant and the Company will be required to issue to Investor one (1) ordinary share for every five (5) outstanding Warrant Shares exercised under the Warrant after sending the Company a notice of the breach and an opportunity to cure within five (5) trading days.

The Warrant and the ordinary shares issuable thereunder, are offered directly to the Investor without a placement agent, underwriter, broker or dealer. We estimate the total expenses of this offering payable by us will be approximately $82,500.

The form of Purchase Agreement is included as an exhibit to our Current Report on Form 6-K that we filed with the SEC in connection with the consummation of this offering. See “Where You Can Find More Information.”

Ordinary Shares issued upon exercise of the Warrant may be offered for sale from time to time after the date of this prospectus by the Investor. The Investor may sell some, all or none of such Ordinary Shares. We do not know how long the Investor will hold any such Ordinary Shares before selling them, and, other than as set forth herein, we currently have no agreements, arrangements or understandings with the Investor regarding the sale or other disposition of any such Ordinary Shares. In addition, except as otherwise disclosed herein, the Investor does not have, and within the past three years has not had, any position, office or other material relationship with us.

The Investor (which includes the pledgees, donees, transferees, assignees, successors and others who later come to hold any of Ordinary Shares issued upon exercise of the Warrant as a result of a transfer not involving a public sale by the Investor) may offer and sell such Ordinary Shares at fixed prices, at prevailing market prices at the time of sale, at prices